當(dāng)前位置：首頁 > 產(chǎn)品中心 > 細(xì)胞培養(yǎng)產(chǎn)品 > 類器官/干細(xì)胞培養(yǎng)/細(xì)胞培養(yǎng) > 類器官CHIR-99021
簡要描述：類器官CHIR-99021類器官（Organoids）是指將成體干細(xì)胞或多能干細(xì)胞在體外三維培養(yǎng)形成的具有一定空間結(jié)構(gòu)的組織類似物。類器官在組織結(jié)構(gòu)、細(xì)胞類型、自我更新能力和功能等方面與來源組織高度一致，從而在發(fā)育生物學(xué)、疾病造模、精準(zhǔn)醫(yī)學(xué)、藥物研發(fā)、基因和細(xì)胞療法、感染和免疫以及再生醫(yī)學(xué)等生物醫(yī)學(xué)的多個(gè)領(lǐng)域展現(xiàn)出*的優(yōu)勢。
產(chǎn)品型號：廠商性質(zhì)：代理商更新時(shí)間：2024-11-06訪 問 量：768產(chǎn)品分類
Product Category相關(guān)文章
Related Articles詳細(xì)介紹
| 品牌 | 其他品牌 | 供貨周期 | 現(xiàn)貨 |
|---|
類器官CHIR-99021
類器官（Organoids）是指將成體干細(xì)胞或多能干細(xì)胞在體外三維培養(yǎng)形成的具有一定空間結(jié)構(gòu)的組織類似物。類器官在組織結(jié)構(gòu)、細(xì)胞類型、自我更新能力和功能等方面與來源組織高度一致，從而在發(fā)育生物學(xué)、疾病造模、精準(zhǔn)醫(yī)學(xué)、藥物研發(fā)、基因和細(xì)胞療法、感染和免疫以及再生醫(yī)學(xué)等生物醫(yī)學(xué)的多個(gè)領(lǐng)域展現(xiàn)出*的優(yōu)勢。
產(chǎn)品介紹DESCRIPTION
| Background | CHIR-99021 is a potent and selective GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib enhances mouse and human embryonic stem cells self-renewal. Laduviglusib induces autophagy[1][2][3]. | ||
| Alias | Laduviglusib; CT99021 | ||
| M. W t | 465.34 | ||
| Formula | C22H18Cl2N8 | ||
| CAS No | 252917-06-9 | ||
| Storage | Powder | -20°C | 3 years |
| 4°C | 2 years C22H18Cl2N8 | ||
| In solvent | -80°C | 6 months | |
| -20°C | 1 month | ||
| Solubility | DMSO | 16.67 mg/mL(35.82 mM) | |
| H2O | < 0.1 mg/mL(insoluble) | ||
BIOLOGICAL ALTIVITY
In Vitro
CHIR-99021 inhibits human GSK-3β with Ki values of 9.8 nM[1]. Laduviglusib is a small organic molecule that inhibits GSK3α and GSK3β by competing for their ATP-binding sites.In vitro kinase assays reveal that Laduviglusib specifically inhibits GSK3β (IC50=~5 nM) and GSK3α (IC50=~10 nM), with little effect on other kinases[4]. In the presence of Laduviglusib the viability of the ES-D3 cells is reduced by 24.7% at 2.5 μM, 56.3% at 5 μM, 61.9% at 7.5 μM and 69.2% at 10 μM Laduviglusib with an IC50 of 4.9 mm[2].
In Vivo
In ZDF rats, a single oral dose of Laduviglusib (16 mg/kg or 48 mg/kg) rapidly lowers plasma glucose, with a maximal reduction of nearly 150 mg/dl 3-4 h after administration[1]. Laduviglusib (2 mg/kg) given once, 4 h before irradiation, significantly improves survival after 14.5 Gy abdominal irradiation (ABI). Laduviglusib treatment significantly blocks crypt apoptosis and accumulation of p-H2AX+ cells, and improves crypt regeneration and villus height. Laduviglusib treatment increases Lgr5+ cell survival by blocking apoptosis, and effectively prevents the reduction of Olfm4, Lgr5 and CD44 as early as 4 h[5].
類器官CHIR-99021
產(chǎn)品咨詢
掃一掃，關(guān)注微信
電話
微信掃一掃